Healthcare Losers: BioTime (NYSEMKT:BTX), Oramed Pharmaceuticals (NASDAQ:ORMP), Anika Therapeutics (NASDAQ:ANIK), WuXi PharmaTech (NYSE:WX), Corcept Therapeutics (NASDAQ:CORT)

Posted by on Jun 14, 2014

BioTime, Inc. (NYSEMKT:BTX) announced that Pedro Lichtinger has been appointed President and Chief Executive Officer of its subsidiary Asterias Biotherapeutics, Inc. (“Asterias”), effective June 9, 2014. BioTime, Inc. (NYSEMKT:BTX) weekly performance is 0.70%. On last trading day company shares ended up $2.87. BioTime, Inc. (NYSEMKT:BTX) distance from 50-day simple moving average is 6.13%.

Aegis Capital affirms its Buy rating on Oramed Pharmaceuticals (Nasdaq:ORMP) while modulating its 12-month price target of $35 out to a 15-month price target of $32. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) shares fell -12.76% in last trading session and ended the day on $9.64. ORMP its return on assets is -64.00%. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) quarterly performance is -14.99%.

Analysts at Singular Research upped their price target on shares of Anika Therapeutics (NASDAQ:ANIK) from $43.50 to $54.00 in a research report issued to clients and investors on Wednesday. Anika Therapeutics, Inc. (NASDAQ:ANIK) shares moved down -5.28% in last trading session and was closed at $44.87, while trading in range of $43.95-$47.70. Anika Therapeutics, Inc. (NASDAQ:ANIK) year to date performance is 17.58%.

On May 30, 2014 WuXi PharmaTech announced in a press release that it has opened a new facility in Shanghai for high-potency active pharmaceutical ingredient (HPAPI) processing. WuXi’s subsidiary, Syn-The-All Pharmaceutical Co. is now processing small molecules at kilogram scale for clinical-trial supply. WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE:WX) ended the last trading day at $30.47. Company weekly volatility is calculated as 4.17% and price to cash ratio as 5.15. WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE:WX) showed a negative weekly performance of -8.83%.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.02. The company had revenue of $4.41 million for the quarter, compared to the consensus estimate of $5.01 million. Corcept Therapeutics Incorporated (NASDAQ:CORT) weekly performance is 7.46%. On last trading day company shares ended up $2.45. Analysts mean target price for the company is $2.80. Corcept Therapeutics Incorporated (NASDAQ:CORT) distance from 50-day simple moving average is -18.40%.

Leave a Reply

Your email address will not be published. Required fields are marked *